8 completed, 2 unknown, 1 terminated. 11 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 11 | Completed 8, Unknown 2, Terminated 1 |
Follow Pneumonia, Pneumococcal: new trials by email Literature Review of Pneumonia, Pneumococcal trials Research Report on Pneumonia, Pneumococcal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4 COVAX+PPV23;COVAX+IIV4, COVAX only (1st and 2nd dose), PPV23 for the 1st dose and IIV4 for the 2nd dose - Influenza, Human, Pneumonia, Pneumococcal | Phase 4 | Unknown | China National Biotec Group Company Limited | 1404 | 2021-05-06 | 2021-10-15 |
| Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4 COVAX+IIV4; COVAX+PPV23, COVAX only (1st and 2nd dose), IIV4 for the 1st dose and PPV23 for the 2nd dose - Influenza, Human, Pneumonia, Pneumococcal | Phase 4 | Completed | China National Biotec Group Company Limited | 1133 | 2021-03-10 | 2021-10-20 |
| Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4 IIV4 and PPV23, IIV4, PPV23 - Influenza, Human, Pneumonia, Pneumococcal | Phase 4 | Completed | China National Biotec Group Company Limited | 1224 | 2020-09-11 | 2022-08-02 |
| Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Vaccination with pneumococcal conjugate vaccine (PCV13), Standard Antibacterial Prophylaxis - Multiple Myeloma, Pneumococcal Infection | Phase 4 | Completed | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | 36 | 2018-07-01 | 2022-08-31 |
| Evaluation of PCV Schedules in a Naive Population in Vietnam PCV 2p+1, PCV 3p+0, PCV 1p+1 - Pneumonia, Pneumococcal | Phase 4 | Completed | Nagasaki University | 18652 | 2016-10-01 | 2024-04-19 |
| The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®, Sequential administration of Pneumovax NP® and Fluvic HA syringe® - Pneumococcal Pneumonia, Influenza | Phase 4 | Completed | Kameda Medical Center | 162 | 2015-11-01 | 2019-01-31 |
| PCV10 Reactogenicity and Immunogenicity Study - Malindi PCV10 and DTaP, hepatitis A vaccine, DTaP, PCV10 - Pneumococcal Pneumonia | Phase 4 | Unknown | KEMRI-Wellcome Trust Collaborative Research Program | 600 | 2010-01-01 | 2018-02-23 |
| Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults VACCINE: placebo, VACCINE: 13-valent pneumococcal conjugate vaccine - Pneumonia, Pneumococcal, Pneumococcal Infections | Phase 4 | Completed | Pfizer | 84496 | 2008-09-01 | 2014-10-06 |
| Targeting of Immune Response After Pneumococcal Vaccination Pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine - Pneumococcal Pneumonia | Phase 4 | Completed | Helsinki University Central Hospital | 42 | 2005-01-01 | 2011-07-26 |
| Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia levofloxacin, ceftriaxone - Pneumonia, Pneumococcal | Phase 4 | Terminated | Hospital Mutua de Terrassa | 45 | 2004-08-01 | 2007-02-01 |
| Humoral Determinants of Immunity to Pneumococcal Infection Prevnar, Pneumovax - Pneumonia, Pneumococcal Infections | Phase 4 | Completed | VA Office of Research and Development | 114 | 2003-01-01 | 2017-09-05 |
Influenza, Human (4) · Pneumococcal Infections (3) · Pneumonia (2) · COVID-19 (1) · Febrile Neutropenia (1) · Multiple Myeloma (1)
Bacterial Infections (11) · Bacterial Infections and Mycoses (11) · Gram-Positive Bacterial Infections (11) · Infections (11) · Lung Diseases (11) · Pneumonia, Bacterial (11) · Respiratory Tract Diseases (11) · Respiratory Tract Infections (11) · Streptococcal Infections (11) · Pneumonia (9) · Pneumococcal Infections (8) · Orthomyxoviridae Infections (4) · RNA Virus Infections (4) · Virus Diseases (4) · Agranulocytosis (1)
Pneumococcal Vaccines (3) · Heptavalent Pneumococcal Conjugate Vaccine (2) · PHiD-CV vaccine (2) · 10-valent pneumococcal conjugate vaccine (1) · Ceftriaxone (1) · Hepatitis A Vaccines (1) · Levofloxacin (1) · Vaccination (1)
China National Biotec Group Company Limited (3) · Helsinki University Central Hospital (1) · Hospital Mutua de Terrassa (1) · KEMRI-Wellcome Trust Collaborative Research Program (1) · Kameda Medical Center (1) · Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology (1) · Nagasaki University (1) · Pfizer (1) · VA Office of Research and Development (1)
China (3) · Belarus (1) · Finland (1) · Japan (1) · Kenya (1) · Netherlands (1) · Spain (1) · United States (1) · Vietnam (1)
Anatoly Uss, MD/PhD (1) · Anu Kantele, MD PhD (1) · Daniel M Musher (1) · Kei Nakashima, MD (1) · Laura Hammitt, MD (1) · Shanying Zhang (1) · Xiaodong Sun (1)
PMID 14998500, PMID 20686433, PMID 24086113, PMID 24465570, PMID 25785969, PMID 26083474, PMID 28173960, PMID 28410813, PMID 29017280, PMID 29429807, PMID 29561248, PMID 32418789, PMID 35931636, PMID 37780234, PMID 39602629, PMID 40396505, PMID 42202846